Health-Economic Challenges for New Alzheimer’s Disease Treatments - 15/04/26
Doi : 10.1016/j.tjpad.2026.100575
Jinjing Fu 1, Anders Skoldunger 2, Angela Bradshaw 3, Hana Marie Broulíková 4, 5, Chiara C Brück 6, Jack M. Chapel 7, Sabine Grimm 8, Anna Hansson 2, William L. Herring 2, 9, Jakub Hlávka 10, Men Thi Hoang 11, 12, Linus Jönsson 2, Filipa Landeiro 13, Javier Mar 14, Alison McKean 15, Matej Misik 10, Peter Neumann 16, Thomas Rapp 17, Craig Ritchie 18, 19, Anja Schiel 20, Yi Sun 21, Dominic Trépel 11, 22, David Trueman 23, P.J. van der Veere 24, 25, Lynn van Rosmalen 6, Jean L Vonsy 26, Lizzie Walker 27, Anders Wimo 28, Bengt Winblad 28, Xin Xia 28, Ron Handels 29, ⁎ 
1 University Medical Center Groningen, Groningen, The Netherlands
2 Karolinska Institutet, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Solna, Sweden
3 Alzheimer Europe, Senningerberg, Luxembourg
4 National Institute of Mental Health, Klecany, Czechia
5 Faculty of Science, Vrije Universiteit Amsterdam, The Netherlands
6 Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands
7 University of Southern California, Los Angelos, United States
8 Maastricht University Medical Centre+, Maastricht, Netherlands
9 Health Economics, RTI Health Solutions, 3040 East Cornwallis Road, Research Triangle Park, NC 27709, USA
10 Health Economics, Policy and Innovation Institute, Masaryk University, Brno, Czech Republic
11 Trinity College Dublin, School of Medicine, Dublin, Ireland
12 Manchester Centre for Health Economics, The University of Manchester, Greater Manchester, United Kingdom
13 Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
14 Biogipuzkoa Health Research Institute, Donostia-San Sebastián, Spain
15 Alzheimer Scotland, Edinburgh, Scotland
16 Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, United States
17 LIRAES and Chaire AgingUP!, Université Paris Cité, Paris, France
18 Scottish Brain Sciences, Edinburgh, United Kingdom
19 University of St Andrews, St Andrews, Scotland, United Kingdom
20 Norwegian Medical Products Agency, Oslo, Norway
21 Department of Economics, University of Reading, United Kingdom
22 Global Brain Health Institute, Dublin, Ireland
23 Source Health Economics, London, United Kingdom
24 Alzheimer Center Amsterdam, Department of Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, De Boelelaan 1118, 1081 HZ, Amsterdam, the Netherlands
25 Department of Epidemiology and Data Science, Amsterdam UMC, De Boelelaan 1117, 1081 HV, Amsterdam, the Netherlands
26 InRAD Foundation, Deventer, The Netherlands
27 National Institute for Health and Care Excellence, London, United Kingdom
28 Division for Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden
29 Maastricht University, Alzheimer Centre Limburg, Faculty of Health Medicine and Life Sciences, Mental Health and Neuroscience Research Institute, Department of Psychiatry and Neuropsychology, Maastricht, The Netherlands
⁎ Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Sous presse. Manuscrit accepté.
Disponible en ligne depuis le Wednesday 15 April 2026
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Keywords : Health economics, Alzheimer's disease, cost-effectiveness modeling, Real-World Evidence
Le texte complet de cet article est disponible en PDF.
Plan
© 2026
Publié par Elsevier Masson SAS.
Bienvenue sur EM-consulte, la référence des professionnels de santé.